Navigation Links
IGI Laboratories, Inc. Receives Formal US FDA Approval For Site Transfer Of Econazole Nitrate
Date:11/1/2013

BUENA, N.J., Nov. 1, 2013 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has received formal approval from the U.S. Food and Drug Administration (FDA) of its supplemental filing for the site transfer of econazole nitrate cream 1%, to the company's manufacturing facility in Buena, NJ.  IGI had purchased econazole nitrate cream 1% from Prasco, LLC in February of 2013. 

(Logo: http://photos.prnewswire.com/prnh/20130827/MM70487LOGO)

Jason Grenfell-Gardner, President and CEO of the Company, commented, "This approval marks the first time the FDA has granted an approval to an IGI own-label project. In less than eight months, we successfully completed all the required steps to achieve approval from the FDA to manufacture our first proprietary IGI label product.  This accomplishment is a testament to the dedication and efforts of our entire team.  We are currently actively manufacturing, marketing and selling this product through our existing commercial infrastructure."

About IGI Laboratories, Inc.

IGI Laboratories is a generic topical pharmaceutical company.  We develop and manufacture topical formulations for the pharmaceutical, OTC, and cosmetic markets. Our mission is to be a leading player in the generic topical prescription drug market.

Forward-Looking Statements

This press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this press release that are not historical facts and statements identified by words such as "plan," "believe," "continue", "should" or words of similar meaning. Factors that could cause actual results to differ materially from these expectations include, but are not limited to: our inability to meet current or future regulatory requirements in connection with existing or future ANDAs; our inability to achieve profitability; our failure to obtain FDA approvals as anticipated; our inability to execute and implement our business plan and strategy; the potential lack of market acceptance of our products; our inability to protect our intellectual property rights; changes in global political, economic, business, competitive, market and regulatory factors; and our inability to complete successfully future product acquisitions.  These statements are based on our current beliefs or expectations and are inherently subject to various risks and uncertainties, including those set forth under the caption "Risk Factors" in IGI Laboratories, Inc.'s most recent Annual Report on Form 10-K,  Quarterly Reports on Form 10-Q and other periodic reports we file with the Securities and Exchange Commission.  IGI Laboratories, Inc. does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.


'/>"/>
SOURCE IGI Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. IGI Laboratories, Inc. Announces Twelfth ANDA Submission
2. MO BIO Laboratories, Inc. launches a new kit for isolation of viral nucleic acids from environmental samples
3. Global Vascular Stents Market 2012-2016 Report with Abbott Laboratories, Medtronic Inc. and Boston Scientific Corp. Dominating
4. Charleston Laboratories, Inc. Announces Successful Completion of Pre-IND Meeting on New Migraine Treatment CL-H1T
5. Clontech Laboratories, Inc. Partners With Rubicon Genomics To Increase Speed And Efficiency Of Sample Preparation For RNA Sequencing
6. Besins Healthcare, Shin Nippon Biomedical Laboratories, Ltd Announce Delivery Technology Licensing Agreement for Intranasal Progesterone
7. FDA Grants Charleston Laboratories, Inc. Request for Pre-IND Meeting on New Migraine Treatment
8. Antigen Laboratories, Inc. to be Acquired by Ares Life Sciences
9. Positive Data, Pipeline Improvements & Market Expansion - Research Report on Abbott Laboratories, Stryker Corporation, St. Jude Medical, Cardiovascular Systems and MAKO Surgical
10. Charleston Laboratories, Inc. Begins Enrollment for CL-108 Phase 3 Clinical Trial
11. Charleston Laboratories, Inc. beginnt mit klinischer Phase 3-Studie für CL-108
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... SEOUL, South Korea , Feb. 12, 2016 ... today announced they will form a partnership to ... medicine in cancer. The goal of the collaboration ... with Macrogen,s high-throughput Next Generation Sequencing capabilities toward ... Laboratory Improvement Amendments (CLIA) of 1988 by the ...
(Date:2/12/2016)... Feb. 12 2016  OMS Supply, a large provider ... practitioners, announced today the recent launching of their new ... variety of features that enhance the user experience and ... --> --> ... new company that started in early 2016, they have ...
(Date:2/12/2016)... BUDAPEST , Ungarn, February 12, 2016 ... ein Medizintechnikunternehmen, das sich auf den ungedeckten ... gab heute positive Ergebnisse seines klinischen Forschungsprogramms ... und Asthma-Patienten beschäftigt, ergab Verbesserungen ihrer respiratorischen ... Indiso ltd , ein Medizintechnikunternehmen, das ...
Breaking Medicine Technology:
(Date:2/12/2016)... , ... February 12, 2016 , ... A lot has ... 35 years. A president has access to health and wellness resources most Americans could ... world, no single individual has a schedule as frenetic as the U.S. President. ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... growth in the field of long term care. With that, says Patrick Loughney, ... healthcare professionals in administrative roles in long term care environments. His company, which ...
(Date:2/12/2016)... Aliso Viejo, CA (PRWEB) , ... February 12, 2016 , ... ... by Pixel Film Studios. The new cartoon style themes are great for showcasing pictures, ... with completely customized scene generators, titles like introductions, lower thirds, transitions and a beautiful ...
(Date:2/11/2016)... ... February 12, 2016 , ... Fitbody Personal Training offers outdoor training classes ... way to get fit and healthy. Located in Phoenixville, PA, the classes are structured ... designed for horseback riders who want to lose weight and tone up. This class ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... (DMPG) will use the action analytics leader’s population health solutions, MDinsight® and ... clinical support to the Atlanta-area healthcare system. Details of the contract were not ...
Breaking Medicine News(10 mins):